<DOC>
	<DOC>NCT02738125</DOC>
	<brief_summary>This study assesses the long‐term effectiveness of adalimumab in subjects starting a treatment for ulcerative colitis in real life conditions, namely to describe the time to loss of clinical benefit in a time to event approach.</brief_summary>
	<brief_title>Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Suffering from ulcerative colitis Naïve from Adalimumab Starting a treatment with adalimumab Capable of and willing to grant authorization for use/disclosure of data collected Able to read, understand, and complete patients questionnaires</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>SOTHIS</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Effectiveness</keyword>
</DOC>